Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about How 'self-sabotage' prevents immune response against malaria
New research has revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.
- Read more about Environmental pollution too behind antibiotic resistance?
Can the emergence of antibiotic-resistant bacteria be squarely blamed on the misuse and overuse of antibiotics? No, there is more to the problem than the misuse of common medications, says a University of Georgia researcher.
- Read more about Merck’s investigational Ebola vaccine for Emergency Use Assessment and Listing accepted for review by WHO
Merck, known as MSD outside the United States and Canada, announced that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV?G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).
- Read more about Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma. This marketing authorization expands upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma.
- Read more about Recipharm collaborate with Alcon & acquires facility in France
Recipharm AB, a leading contract development and manufacturing organisation in the pharmaceutical industry, has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology.
- Read more about Sanofi get Philippines approval to market dengue vaccine
Sanofi Pasteur, the vaccines division of Sanofi, announced that the Philippines have granted marketing approval to Dengvaxia®, making it the first vaccine to be licensed for the prevention of dengue in Asia.
- Read more about Novel liver hormone cuts cravings for sweets, alcohol
In a good news for those who cannot shun their drink and also have "sweet tooth", scientists have discovered for the first time a liver hormone that works via brain to reduce cravings for sweets and alcohol in mammals.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Marijuana derivative can safely reduce epilepsy seizures
A medical marijuana derivative was found safe and effective in reducing the frequency of seizures in most children and young adults enrolled in a year-long study led by epilepsy specialists in the US.
- Read more about Iran's Pharmaceutical sector to become a pharma powerhouse post sanction era - Biotechnology sector to have lucrative opportunities
With annual consumption of 30 billion units of various generic medicines, Iran, the second-biggest consumer of generics in the Asian continent spent over USD 4.5 billion on drugs in 2015. While per capita consumption of generic drugs is three times higher than average per capita consumption in the world, biological medicines and drugs for special diseases suffers from limited access. Cardiovascular, Anti-Cancer & chemotherapy drugs, MAB, pain relievers & Hydrocortisones, Anti infections, Plasma products & Recombinants as well as Diabetes control over 55% of the total sales market. Solid dose (Tablet &Capsules) and injection forms control 42% and 38% of total sales market, respectively.
- Read more about Biocon introduces CIMIVIR-L™ for Hepatitis-C in India
Biocon Ltd, Asia's premier biotechnology company, introduces an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of the innovator product commercialized by Gilead Sciences in the US.